Bimatoprost
Brand name: Lumigan
Rank #64 of 500 drugs by total cost
$284.4M
Total Cost
610,243
Total Claims
$284.4M
Total Cost
9,710
Prescribers
$466
Cost per Claim
133,958
Beneficiaries
1,059,475
30-Day Fills
$29K
Avg Cost/Provider
63
Avg Claims/Provider
About Bimatoprost
Bimatoprost (sold as Lumigan) was prescribed 610,243 times by 9,710 Medicare Part D providers in 2023, costing the program $284.4M. At $466 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
| 63 | Rsv Vacc, Pref A And Pref B/Pf (Abrysvo) | $284.5M | 872,396 |
| 64 | Bimatoprost (Lumigan) | $284.4M | 610,243 |
| 65 | Apremilast (Otezla) | $283.9M | 59,020 |
| 66 | Budesonide/Glycopyr/Formoterol (Breztri Aerosphere) | $280.9M | 340,138 |
| 67 | Selexipag (Uptravi) | $279.1M | 12,320 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology